A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Progyny, Inc.
PGNY
$2.8B
Mkt Cap
$31.19
+1.60%
Progyny, Inc. (PGNY) has a current P/E ratio of 48.0, compared to its historical median P/E of 60.9. The stock is currently considered Fair based on its historical valuation range.
Progyny, Inc. (PGNY) has a 5-year average return on invested capital (ROIC) of 24.3%. This indicates strong capital allocation and a potential competitive advantage.
Progyny, Inc. (PGNY) has a market capitalization of $2.4B. It is classified as a mid-cap stock.
Progyny, Inc. (PGNY) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 8.20%.
Based on historical P/E analysis, Progyny, Inc. (PGNY) appears fair. The current P/E of 48.0 is 21% below its historical median of 60.9. The estimated fair value CAGR (P/E method) is 41.8%.
Progyny, Inc. (PGNY) operates in the Services-Misc Health & Allied Services, Nec industry, within the Healthcare sector.
Progyny, Inc. (PGNY) reported annual revenue of $1.3 billion in its most recent fiscal year, based on SEC EDGAR filings.
Progyny is a global leader in women’s health and family building solutions. We envision a world where everyone can realize their dreams of family and ideal health. Our mission is to empower healthier, supported journeys through transformative fertility, family building and women’s health benefits. Through our differentiated approach to benefits plan design, member education and support and active network management, our clients’ employees are able to pursue the most effective treatment across life’s milestones from the best providers and specialists and achieve optimal outcomes. We launched our fertility benefits solution in 2016 with five employer clients and have since expanded our platform to include solutions in pregnancy and postpartum, menopause and midlife, benefit and leave navigation and parent and child wellbeing in order to address the continuum of women’s health.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 1.3B | 1.3B | 1.2B | 1.1B | 787M | 501M |
| Net Income | 68M | 59M | 54M | 62M | 30M | 66M |
| EPS | $0.82 | $0.65 | $0.57 | $0.62 | $0.30 | $0.66 |
| Free Cash Flow | 184M | 192M | 174M | 185M | 77M | 24M |
| ROIC | 28.8% | 24.4% | 22.3% | 28.0% | 14.2% | 32.6% |
| Gross Margin | 24.1% | 23.6% | 21.7% | 21.9% | 21.3% | 22.4% |
| Debt/Equity | 0.00 | 0.05 | 0.05 | 0.04 | 0.02 | 0.03 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 96M | 85M | 67M | 62M | 23M | 32M |
| Operating Margin | 7.5% | 6.6% | 5.8% | 5.7% | 3.0% | 6.5% |
| ROE | 15.4% | 12.5% | 11.1% | 13.3% | 9.7% | 31.4% |
| Shares Outstanding | 78M | 90M | 95M | 100M | 101M | 100M |
| Metric | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | N/A | N/A | N/A | 345M | 501M | 787M | 1.1B | 1.2B | 1.3B | 1.3B |
| Gross Margin | N/A | N/A | N/A | 20.3% | 22.4% | 21.3% | 21.9% | 21.7% | 23.6% | 24.1% |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 9.5M | 9.5M |
| SG&A | 14M | 16M | 24M | 47M | 60M | 98M | 117M | 122M | 147M | 144M |
| EBIT | -11M | -3.5M | 9.7M | 8.3M | 32M | 23M | 62M | 67M | 85M | 96M |
| Op. Margin | N/A | N/A | N/A | 2.4% | 6.5% | 3.0% | 5.7% | 5.8% | 6.6% | 7.5% |
| Net Income | -13M | -5.5M | -8.6M | 46M | 66M | 30M | 62M | 54M | 59M | 68M |
| Net Margin | N/A | N/A | N/A | 13.5% | 13.1% | 3.9% | 5.7% | 4.7% | 4.5% | 5.2% |
| Non-Recurring | -2K | 0 | -1K | 0 | 0 | 0 | 0 | -1.4M | -79K | -79K |
| Returns on Capital | ||||||||||
| ROIC | N/M | -8.4% | 6.7% | 33.0% | 32.6% | 14.2% | 28.0% | 22.3% | 24.4% | 28.8% |
| ROE | 13.8% | 5.7% | -89.5% | 33.0% | 31.4% | 9.7% | 13.3% | 11.1% | 12.5% | 15.4% |
| ROA | -897.9% | -25.9% | -8.9% | 23.0% | 21.5% | 6.7% | 9.5% | 8.0% | 8.7% | 9.7% |
| Cash Flow | ||||||||||
| Op. Cash Flow | -9.5M | 2.3M | -1.5M | 36M | 26M | 80M | 189M | 179M | 210M | 206M |
| Free Cash Flow | -10M | 1.7M | -4.5M | 35M | 24M | 77M | 185M | 174M | 192M | 184M |
| Owner Earnings | -13M | -2.6M | -8.7M | 21M | -9.0M | -22M | 64M | 48M | 73M | 82M |
| CapEx | 612K | 579K | 3.0M | 1.0M | 2.1M | 3.2M | 3.6M | 5.4M | 18M | 22M |
| Maint. CapEx | 1.6M | 1.9M | 2.1M | 1.9M | 1.3M | 1.6M | 2.3M | 3.2M | 4.9M | 5.3M |
| Growth CapEx | 0 | 0 | 823K | 0 | 828K | 1.6M | 1.4M | 2.2M | 13M | 17M |
| D&A | 1.6M | 1.9M | 2.1M | 1.9M | 1.3M | 1.6M | 2.3M | 3.2M | 4.9M | 5.3M |
| CapEx/OCF | N/A | N/A | N/A | 2.9% | 8.2% | 4.0% | 1.9% | 3.0% | 8.8% | 10.6% |
| Capital Allocation | ||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 1.2M | 185K | 0 | 0 | 0 | 0 | 300M | 82M | 200M |
| Buyback Yield | 0.0% | N/A | 0.0% | N/A | N/A | N/A | N/A | 18.6% | 3.5% | 8.2% |
| Stock-Based Comp | 1.6M | 3.0M | 5.1M | 13M | 34M | 101M | 123M | 128M | 132M | 119M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.1M | 3.1M |
| Balance Sheet | ||||||||||
| Net Debt | -1.4M | 5.2M | N/A | -100M | -111M | -182M | -352M | -209M | -282M | -225M |
| Cash & Equiv. | 4.7M | 127K | 80M | 70M | 91M | 120M | 97M | 162M | 112M | 225M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | -0.03 | -0.06 | 0.32 | 0.06 | 0.03 | 0.02 | 0.04 | 0.05 | 0.05 | 0.00 |
| Interest Coverage | -14.9 | -6.9 | 166.8 | 69.0 | 70.2 | 28.7 | 18.8 | N/A | N/A | N/A |
| Equity | -98M | -95M | 114M | 167M | 252M | 377M | 553M | 422M | 516M | 439M |
| Total Assets | 1.5M | 41M | 150M | 254M | 358M | 543M | 757M | 607M | 742M | 698M |
| Total Liabilities | 99M | 30M | 36M | 87M | 106M | 166M | 203M | 185M | 226M | 259M |
| Intangibles | N/A | 3.9M | 2.4M | 1.2M | 599K | 99K | 0 | 1.3M | 6.2M | 6.0M |
| Retained Earnings | N/A | -105M | -113M | -68M | -2.4M | 28M | 90M | 144M | 203M | 227M |
| Working Capital | N/A | -5.7M | 96M | 112M | 160M | 274M | 454M | 304M | 349M | 266M |
| Current Assets | 279K | 25M | 132M | 190M | 259M | 434M | 640M | 473M | 552M | 502M |
| Current Liabilities | N/A | 30M | 36M | 78M | 99M | 160M | 186M | 169M | 202M | 236M |
| Per Share Data | ||||||||||
| EPS | -2.37 | -1.07 | -0.10 | 0.47 | 0.66 | 0.30 | 0.62 | 0.57 | 0.65 | 0.82 |
| Owner EPS | -2.22 | -0.51 | -0.10 | 0.22 | -0.09 | -0.22 | 0.64 | 0.50 | 0.82 | 1.05 |
| Book Value | -17.18 | -18.45 | 1.36 | 1.69 | 2.53 | 3.73 | 5.53 | 4.43 | 5.73 | 5.61 |
| Cash Flow/Share | -1.67 | 0.44 | -0.02 | 0.37 | 0.26 | 0.79 | 1.89 | 1.88 | 2.33 | 0.93 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 5.7M | 5.2M | 84.2M | 98.8M | 99.7M | 101.2M | 100.1M | 95.3M | 90.0M | 78.3M |
| Valuation | ||||||||||
| P/E Ratio | N/A | N/A | N/A | 89.1 | 79.4 | 101.4 | 60.9 | 29.6 | 39.7 | 38.1 |
| P/FCF | N/A | N/A | N/A | 117.7 | 218.4 | 39.9 | 20.4 | 9.3 | 12.1 | 13.2 |
| EV/EBIT | N/A | N/A | 235.3 | N/A | N/A | N/A | N/A | N/A | N/A | 23.0 |
| Price/Book | N/A | N/A | 21.3 | 24.8 | 20.7 | 8.2 | 6.8 | 3.8 | 4.5 | 5.6 |
| Price/Sales | N/A | N/A | 9.0 | 7.9 | 10.6 | 4.9 | 3.2 | 2.2 | 1.6 | 1.9 |
| FCF Yield | N/A | N/A | -0.2% | 0.8% | 0.5% | 2.5% | 4.9% | 10.8% | 8.3% | 7.6% |
| Market Cap | 0 | N/A | 2.4B | 4.1B | 5.2B | 3.1B | 3.8B | 1.6B | 2.3B | 2.4B |
| Avg. Price | 0.00 | N/A | 23.80 | 27.48 | 53.45 | 38.31 | 35.06 | 26.83 | 22.23 | 31.19 |
| Year-End Price | 0.00 | N/A | 27.95 | 41.89 | 52.41 | 30.42 | 37.75 | 16.90 | 25.80 | 31.19 |
Progyny, Inc. passes 8 of 9 quality checks, indicating strong fundamentals.
Progyny, Inc. trades at 48.0x trailing earnings, compared to its 15-year median P/E of 60.9x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 13.3x vs a median of 16.3x. The company's 5-year average ROIC is 24.3% with a gross margin of 22.2%. Total shareholder yield (buybacks) is 8.2%. At current prices, the estimated annualized return to fair value is +61.2%.
Progyny, Inc. (PGNY) has a net profit margin of 4.5%. This is a modest margin.
Progyny, Inc. (PGNY) generated $192 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Progyny, Inc. (PGNY) has a debt-to-equity ratio of 0.05. This indicates a conservatively financed balance sheet.
Progyny, Inc. (PGNY) reported earnings per share (EPS) of $0.65 in its most recent fiscal year.
Progyny, Inc. (PGNY) has a return on equity (ROE) of 12.5%. This indicates moderate shareholder returns.
Progyny, Inc. (PGNY) has a 5-year average gross margin of 22.2%. This lower margin is typical of capital-intensive or commodity businesses.
The Ledger Terminal provides 9 years of financial data for Progyny, Inc. (PGNY), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Progyny, Inc. (PGNY) has a book value per share of $5.73, based on its most recent annual SEC filing.